Novartis has agreed to pay BoomRay up to $900 million for exclusive global rights to an undisclosed preclinical radioligand therapy asset.

Merck has acquired exclusive global rights to SciBrunch's preclinical KRAS G12D inhibitor SPR2015.

Two FDA approvals, six platform deals, a European alarm, a Novo listing debate, and a China mega-deal — this week's biggest pharma stories, explained.

New U.S. guidance exempts orphan drugs, nuclear medicines, cell and gene therapies, and other specialty products from the 100% pharmaceutical tariff when imported from 19 named countries.

Novo licensed Hengrui's once-weekly oral GLP-1/GIP dual agonist HRS-1596 in a deal worth up to $2.6 billion, while AstraZeneca invested $2 billion in Summit Therapeutics to pair ivonescimab with its antibody-drug conjugate portfolio.

Adding oral L-glutamine to standard chemo nearly tripled median OS in advanced pancreatic cancer — and what comes next.

Eli Lilly is set to pay InnoCare Pharma up to $3.35 billion to discover and develop compounds against upwards of five undisclosed targets.

Why self-reported data fails clinical trials — and how RWD and AI fix enrollment accuracy before the first patient is dosed.